A Simplified 4-Site Economical Intradermal Post-Exposure Rabies Vaccine Regimen: A Randomised Controlled Comparison with Standard Methods by Warrell, Mary J. et al.
A Simplified 4-Site Economical Intradermal Post-
Exposure Rabies Vaccine Regimen: A Randomised
Controlled Comparison with Standard Methods
Mary J. Warrell
1, Anna Riddell
1, Ly-Mee Yu
2, Judith Phipps
1, Linda Diggle
1, Herve ´ Bourhy
3, Jonathan J.
Deeks
2, Anthony R. Fooks
4, Laurent Audry
3, Sharon M. Brookes
4, Franc ¸ois-Xavier Meslin
5, Richard
Moxon
1, Andrew J. Pollard
1, David A. Warrell
1*
1The Oxford Vaccine Group, Centre for Clinical Vaccinology & Tropical Medicine University of Oxford, Churchill Hospital, Oxford, United Kingdom, 2Centre for Statistics in
Medicine, University of Oxford, Oxford, United Kingdom, 3UPRE Lyssavirus Dynamics and Host Adaptation, WHO Collaborating Centre for Reference and Research on
Rabies, Institut Pasteur, Paris, France, 4Rabies and Wildlife Zoonoses Group, WHO Collaborating Centre for the Characterization of Rabies and Rabies-Related Viruses,
Veterinary Laboratories Agency, Weybridge, United Kingdom, 5Zoonoses and VPH, Department of Food Safety, Zoonoses and Foodborne Diseases, World Health
Organization, Geneva, Switzerland
Abstract
Background: The need for economical rabies post-exposure prophylaxis (PEP) is increasing in developing countries.
Implementation of the two currently approved economical intradermal (ID) vaccine regimens is restricted due to confusion
over different vaccines, regimens and dosages, lack of confidence in intradermal technique, and pharmaceutical regulations.
We therefore compared a simplified 4-site economical PEP regimen with standard methods.
Methods: Two hundred and fifty-four volunteers were randomly allocated to a single blind controlled trial. Each received
purified vero cell rabies vaccine by one of four PEP regimens: the currently accepted 2-site ID; the 8-site regimen using 0.05 ml
per ID site; a new 4-site ID regimen (on day 0, approximately 0.1 ml at 4 ID sites, using the whole 0.5 ml ampoule of vaccine; on
day 7, 0.1 ml ID at 2 sites and at one site on days 28 and 90); or the standard 5-dose intramuscular regimen. All ID regimens
required the same total amount of vaccine, 60% less than the intramuscular method. Neutralising antibody responses were
measured five times over a year in 229 people, for whom complete data were available.
Findings: All ID regimens showed similar immunogenicity. The intramuscular regimen gave the lowest geometric mean
antibodytitres.Usingthe rapid fluorescentfocusinhibition test, someserahad unexpectedly highantibodylevels thatwere not
attributable to previous vaccination. The results were confirmed using the fluorescent antibody virus neutralisation method.
Conclusions: This 4-site PEP regimen proved as immunogenic as current regimens, and has the advantages of requiring
fewer clinic visits, being more practicable, and having a wider margin of safety, especially in inexperienced hands, than the
2-site regimen. It is more convenient than the 8-site method, and can be used economically with vaccines formulated in 1.0
or 0.5 ml ampoules. The 4-site regimen now meets all requirements of immunogenicity for PEP and can be introduced
without further studies.
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Introduction
Rabies is a neglected disease affecting particularly tropical
developing countries [1]. Estimates of the Global use of rabies
post-exposure prophylaxis (PEP) are rising. In China, it was 8
million in 2005 [2], yet rabies currently kills more people than any
other infectious disease there. Rabies deaths are underreported
and misdiagnosed, for example as cerebral malaria [3]. As the
obsolete nervous tissue-based rabies vaccines are replaced by
expensive tissue culture vaccines, there is increasing need to
www.plosntds.org 1 April 2008 | Volume 2 | Issue 4 | e224reduce the cost of post-exposure prophylaxis. In Africa, the
average cost of a standard intramuscular (IM) course of vaccine is
$39.6, equivalent to 50 days wages [1]. There is a shortage of
affordable rabies vaccines of reliable quality in the developing
world [4].
Economical PEP regimens employ multiple site intradermal
(ID) injections, saving 60% of the vaccine used in the standard IM
method (Table 1). Increasing the number of sites of injection is
designed to stimulate several different groups of lymph nodes to
initiate antibody production. Two economical regimens are now
recommended [5], an 8-site [6] and a 2-site [7] method (Table 1).
The urgency of PEP demands a rapid induction of neutralising
antibody using minimal amounts of vaccine in all recipients
including the ,3% of the population who are ‘low responders’ [8]
and the many others whose immune response is impaired [9–12].
The original IM PEP vaccine regimen is the most widely used
globally. In Asia only 3% of tissue culture rabies vaccine
treatments use economical ID regimens [1], and they are rarely
used in Africa . The reasons are misgivings about reducing the
vaccine dosage in prevention of a fatal disease [13], confusion over
regimens, and the competence of staff giving ID inoculation.
Economical regimens require sharing of ampoules between
patients, but rabies vaccines have no added preservative and so
the reconstituted ampoule of vaccine should be used within a day.
The use of economical regimens is therefore mainly confined to
large treatment centres, yet 90% of rabies deaths occur in rural
areas [4].
Evidence to date indicates that the 8-site regimen is more
immunogenic than the 2-site regimen [14,15]. However the 8-site
method is not economical when used with one of the two major
vaccines, purified vero cell rabies vaccine (PVRV) (Verorab
TM
Sanofi Pasteur), because this vaccine is relatively concentrated: an
IM dose is 0.5 ml, in contrast to the equivalent 1 ml dose of the
other widely used vaccine, purified chick embryo cell vaccine
(PCECV) (Rabipur
TM; Novartis) [15]. Although the 8-site regimen
has some advantages and was recommended by some authorities
for use when rabies immunoglobulin (RIG) was not available [15],
the 2-site regimen is more acceptable and convenient. The total
dose of vaccine should be the same with the two regimens. The
only difference between the two schedules is that with the 8-site a
large dose of vaccine is given on the first day, whereas with the 2-
site regimen this is divided between days 0 and 3, entailing an
extra treatment visit [14]. Ambrozaitis et al. [16] demonstrated
that the 4-site regimen was apparently immunogenic with both
PVRV and PCEC vaccines, but there was no comparison with any
current PEP method and historical controls are unreliable.
For all these reasons, a single, simple, acceptable, immunogenic
and economical PEP regimen is needed, suitable for use with all
vaccines fulfilling WHO requirements. We tested a 4-site PEP
regimen which allows the 8-site regimen principle to be used
economically with PVRV. We also investigated whether injecting
the same amount of vaccine between 4 instead of 8 sites affected
immunogenicity. The new 4-site regimen and the currently used
ID regimens were compared with the standard IM method in a
single blind, randomised, controlled trial.
Methods
The CONSORT checklist for this study is available in
Supporting Information as Checklist S1.
Participants
Healthy volunteers were recruited in Oxford and Bristol UK,
between June 2002 and April 2005. The exclusion criteria were:
previous rabies vaccine treatment; pregnancy; a recent blood
transfusion; taking immunosuppressive drugs; receiving another
killed vaccine or chloroquine treatment [17] within 2 weeks, or
any live virus vaccine within 3 weeks of a rabies vaccine dose. The
Oxfordshire Clinical Research Ethics Committee approved the
project (ref. C01.078), conducted in accordance with GCP
regulations (EU Directive 2001/20/EC).
Table 1. Vaccine Regimens Showing Number of Sites of Injection.
Regimen Day 0 Day 3 Day 7 Day 14 Day 28 Day 90 Total Ampoules of Vaccine
A 4-site ID 4 (0.5 ml)* 2 1 1 1.8 (0.9 ml)
B 8-site
{ ID 8 (0.5 ml)* 4 1 1 1.6 (0.8 ml)
D 2-site ID 2 (0.2 ml) 2 2 1 1 1.6 (0.8 ml)
E IM 1 (0.5 ml) 1 1 1 1 5
*Whole ampoule of vaccine divided between sites.
{For the 8-site regimen, the intradermal (ID) dose is 0.05 ml per site. All other ID doses are 0.1 ml per site.
ID injection sites over deltoids for 1 or 2 sites. 4 sites are deltoids and thighs.
8 sites are deltoids, thighs, suprascapular, and lower anterior abdominal wall areas. Intramuscular (IM) injection into the left deltoid.
doi:10.1371/journal.pntd.0000224.t001
Author Summary
All human deaths from rabies result from failure to give
adequate prophylaxis. After a rabid animal bite, immediate
wound cleaning, rabies vaccine and immunoglobulin
injections effectively prevent fatal infection. Immunoglob-
ulin is very rarely available in developing countries, where
prevention relies on efficacious vaccine. WHO approved
vaccines are prohibitively expensive, but 2 economical
regimens (injecting small amounts of vaccine intradermal-
ly, into the skin, at 2 or 8 sites on the first day of the
course) have been used for many years in a few places.
Practical or perceived difficulties have restricted wide-
spread uptake of economical methods. These could largely
be overcome by introducing a new, simpler regimen,
involving 4 site injections on the first day. We vaccinated
volunteers to compare the antibody levels induced by the
4-site intradermal regimen with those induced by the
current 2-site and 8-site regimens and the ‘‘gold standard’’
intramuscular regimen favoured internationally. All the
economical intradermal regimens were at least as immu-
nogenic as the intramuscular method. The results provide
sufficient evidence that the 4-site regimen meets the
criteria necessary for its recommendation for use wherever
the cost of vaccine is prohibitive and especially where 2 or
more patients are treated on the same day.
Post-Exposure Intradermal Rabies Vaccine
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Each participant was allocated to one of four rabies PEP regimens
according to a computer generated list with fixed blocksof 12. Group
A received the 4-site regimen; group B, the 8-site regimen; group D,
the 2-site regimen and group E, the IM regimen. Allocations were
concealed in opaque serially numbered sealed envelopes, opened
once written informed consent had been obtained. All laboratory
staff were blinded to the treatment allocation.
Vaccine and regimens
The vaccine used was PVRV, (Verorab
TM Sanofi Pasteur) Lot no
XO291-1 potency 5.3 IU/dose in 165 subjects, and Lot no. U0271
potency 8.4 IU/dose in 64 subjects. The Medicines and Healthcare
products Regulatory Agency granted exemption from a licence.
The 2-site and IM regimens were according to standard
methods (Table 1) [15]. For the 4-site regimen, on day 0 the entire
contents of the 0.5 ml PVRV vial are injected ID, divided between
4 sites over the deltoids and thighs (approximately 0.1 ml per site).
On day 7, 0.1 ml is injected ID at 2 sites (deltoids). Single site
injections are given on days 28 and 90. The 8-site regimen is the
exact equivalent of the current 8-site method [6,15], using a
vaccine containing 0.5 ml/ampoule. The entire contents of the
vial are divided between 8 ID sites on day 0: (deltoids, thighs,
suprascapular, lower anterior abdominal wall). The dose per site is
approximately 0.05 ml. All the ID regimens use the same total
amount of vaccine. There is a little inevitable wastage in syringes.
Opened ampoules were refrigerated and used or discarded within
8 hours. See Table 1 for the timing, doses, routes and sites of
inoculation of all the regimens.
Serology
Blood samples were taken at days 0, 7, 14, 90 and 1 year. Serum
aliquots werecoded, stored at 270uCandassayedblind.Neutralising
antibody levels were measured by an adaptation of the rapid
fluorescent focus inhibition test (RFFIT) for 96 well plates [18,19], at
the Institut Pasteur, Paris. Briefly, a constant dose of challenge virus
standard (CVS) is incubated with diluted test sera. An in-house
reference serum (SHR2 31/03/06=22 IU/ml), is calibrated against
an international standard (RAI=30 IU/ml). Serum/virus mixtures
are incubated, and BSR cells (a clone of BHK-21 cells) were added.
After 24 hours incubation, the monolayer is acetone-fixed and
stained with a fluorescent anti-nucleocapsid antibody (Chemicon).
The result in IU/ml was the mean of independent duplicate tests.
Selected sera were also assessed using the fluorescent antibody
virus neutralisation (FAVN) assay at the Veterinary Laboratories
Agency ,Weybridge [20,21]. This test is the same in principle as
the RFFIT, using the same challenge virus. The FAVN and
RFFIT vary in that they use a different dilution series (3 fold versus
5 fold); the FAVN runs samples in quadruplicate; BHK-21 cells
(ATCC, USA) are used, and the internal serum standard is the
WHO human positive control (NIBSC, UK). The antibody titre is
based on 100% virus neutralisation for the FAVN and 50%
reduction of fluorescent foci in the RFFIT.
Protocol deviations were not permitted on days 7 and 14, but
flexibility was allowed if necessary: on day 2861 day; on day 90 - 7
to +10 days, and at one year 22 weeks to +4 weeks. All records
were kept in strict confidence. Volunteers kept a health record
diary for a week after each vaccine dose.
Statistical methods
The aim was to demonstrate that the 4-site test regimen was at
least as immunogenic as the standard regimens. The primary
outcome is the proportion of participants reaching the WHO
criterion for post-exposure regimens: a minimum neutralising
antibody level of 0.5 IU/ml by day 14. The failure rate for the
current regimen in meeting this threshold isless than one in1000. At
thisrate,theexpected numberoffailuresinthe controlgroupislikely
to be zero. The sample size calculation was based on the assumption
that the new regimen was just as effective (i.e. rate of less than 1 in
1000) and was computed by simulation method using exact methods
for estimating the confidence interval (CI) for the difference.
The initial protocol envisaged the recruitment of 75 participants
per group to make 5 comparisons over 7 regimens expecting zero
events to be observed, giving 90% power to show that the
difference in failure rates was at most 6.2% (adjusting for pre-
planned multiple comparisons). Because the trial failed to recruit
at an adequate rate, the revised sample size of 55 participants per
group (Protocol S1) was calculated for a total of 6 comparisons
among four groups giving 90% power to show that the difference
in failure rates was at most 9% by day 14.
Proportions and 95% CI for the difference in proportions were
calculated using the method based on Wilson’s score [22].
Agreement between the results of the two antibody tests was
assessed by the Bland-Altman method [23]. Titre concentrations
were log transformed and groups were compared using analysis of
variance. Results were deemed statistically significant at P,0.05.
Fisher’s exact test was used to compare side effects between
groups. Post-hoc pairwise comparisons were also carried out on
any local reactions (redness, swelling hardness, or tenderness/pain)
and on any local or generalised signs or symptoms. P-values were
adjusted if multiple comparisons were performed.
Results
Participant flow
Two hundred and fifty four subjects were recruited. Data from
229 were complete up to day 90, and used in the final analysis.
Twenty five were excluded, usually because they failed to keep
appointments (for details see Figure 1). Three sera taken on day 14
were lost during storage.
Subjects were aged between 18 and 50 years. Ages and sex
ratios were similar between the groups (Table 2).
Side effects
One person withdrew within the first week because of transient
arthralgia, possibly related to the vaccine.
Local reactions to the vaccine observed by 229 volunteers are
shown in Table 3. Redness (erythema), swelling (inflammation) and
hardness (induration) were more frequent in all ID groups than in
the IM group (E) (P,0.0001). The incidence of local tenderness or
pain was similar in all groups. Itchiness and local lymphadenopathy
(tenderness at regional lymph nodes) was not solicited, but was
volunteered more often in the ID groups (P,0.0001).
Volunteers were asked to report any generalised symptoms,
whether or not listed in their reaction diary. Some were
attributable to causes unrelated to vaccination. The incidence of
each of the generalised symptoms was lower with the IM regimen
but this only reached significance when compared with all three
ID groups together (P,0.001) (Table 4).
RFFIT serology results
The lower limit of detection of antibody was 0.06 IU/ml, while
the threshold for a positive result, was 0.3 IU/ml, as naı ¨ve sera can
range between 0 and 0.3 IU/ml.
Two sera gave pre-vaccination results above this threshold (the
means of two tests were 0.38 IU/ml and 0.46 IU/ml). These
subjects denied previous rabies immunisation and subsequent
Post-Exposure Intradermal Rabies Vaccine
www.plosntds.org 3 April 2008 | Volume 2 | Issue 4 | e224titres did not suggest a secondary immune response, but they were
excluded from the analysis. Data for the remaining 227 people
were analysed. Undetectable titres were assigned the value of 0.02.
Geometric mean titres (GMTs) on day 7 for the 4 treatment
groups (Table 5, Figure 2), showed that group E (IM) had a lower
GMT than group D (2-site) (P,0.001) and group B (8-site)
(P=0.01). Group A (4-site) was lower than group D (P=0.01).
The percentage of people with detectable antibody .0.3 IU/ml
was 60%, 77.6%, 86.2% and 62.5% for groups A, B, D and E
respectively. The day 7 results were no different with the two
batches of vaccine (data not shown).
On day 14 all subjects had antibody levels .0.5 IU/ml (Table 5,
Figure 2). The 95% confidence intervals for the differences in
proportions between any two regimens indicated that differences
could at most be between 6% and 7% (Figure 3). The only
significant difference between the GMTs is that Group E (IM) was
lower than group D (2-site) (P=0.04).
On day 90, GMTs were similar (Table 5, Figure 2). At 1 year all
ID recipients had detectable antibody, but two people in group E
(IM) had ,0.3 IU/ml. Eight had levels between 0.3 and 0.5 IU/
ml: 2 in group A, 2 in group B and 6 in group E. All the ID
regimens induced more persistent antibody than the IM group
(P,0.001 for groups B and D, P,0.02 for A). The 2-site (D) GMT
was greater than the 4-site (A) (P,0.04).
Before the serological data were decoded, some unusual results
were identified. Antibody levels were unexpectedly high on days 7
and 14, compared with other clinical trials [6,7,16]. Two subjects
were excluded because they had pre-vaccination antibody levels
above the 0.3 IU/ml threshold. Two people had antibody levels
.3000 IU/ml on day 14 (both of them later proved to be in group
D). The next highest were seven subjects with levels between 1000
and 1500 IU/ml. The other results for these people were well
within the range of the rest. After decoding, none of the high
results was found to be among group A subjects. They were
individual high titres, without any suggestion of an anemnestic
response. To confirm the results of the trial, 224 (of the original
229) day 7 samples available, and a few others (see below) were
tested blind in another laboratory which uses the FAVN method.
FAVN serology results and comparison with RFFIT
The FAVN lower limit of detection of antibody was 0.05 IU/
ml. The threshold for a positive result is .0.13 as naı ¨ve sera can
range up to 0.1 IU/ml.
The day 7 results for 224 subjects, including the 2 excluded
because of high initial RFFIT titres, showed GMTs between
1.044 IU/ml for group D (2-site) and 0. 573 IU/ml for E (IM)
(P,0.01) (Table 6, Figure 4). There were no other significant
differences and GMTs were in the same order as the RFFIT
results for all 4 treatment groups. The percentage of people with
detectable antibody, .0.13 IU/ml, was 96.3 %, 93.0%, 96.6 %
and 87.3 % for groups A, B, D and E respectively.
Figure 1. Flow diagram of subjects recruited to rabies vaccine study. Group A received the 4-site regimen; group B, the 8-site regimen;
group D, the 2-site regimen and group E, the IM regimen.
doi:10.1371/journal.pntd.0000224.g001
Table 2. Demographic Characteristics.
Group A
4-site
(n=55)
Group B
8-site
(n=60)
Group D
2-site
(n=58)
Group E
IM (n=56)
Sex
No. Females (%) 34 (61.8) 40 (66.7) 46 (79.3) 32 (57.1)
No. Males (%) 21 (38.2) 20 (33.3) 12 (20.7). 24 (42.9)
Ages (years)
Mean (SD) 28.0 (9.2) 28.8 (9.6) 26.5 (6.9) 31.6 (10.0)
Range 18.3–50.8 19.0–49.4 18.1–44.4 18.1–50.7
doi:10.1371/journal.pntd.0000224.t002
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Reaction Group A 4-site (n=55) Group B 8-site (n=60) Group D 2-site (n=58) Group E IM (n=56) P-value
Redness 53 (96.4%) 58 (96.7%) 54 (93.1%) 14 (25.0%) ,0.0001
Swelling 42 (76.4%) 48 (80.0%) 46 (79.3%) 8 (14.3%) ,0.0001
Hardness 41 (74.6%) 44 (73.3%) 38 (65.5%) 9 (16.1%) ,0.0001
Tenderness/ Pain 39 (70.9%) 35 (58.3%) 41 (70.7%) 31 (55.4%) 0.2
Any above reactions 53 (96.4%) 58 (96.7%) 54 (93.1%) 33 (58.9%) ,0.0001*
Itchiness 26 (47.3%) 29 (48.3%) 28 (48.3%) 2 (3.6%) ,0.0001
Lymphadenopathy 5 (9.1%) 15 (25.0%) 8 (13.8%) 0 (0%) ,0.0001
*Post hoc test: A vs E, P,0.0001; B vs E, P,0.001; D vs E, P,0.001.
doi:10.1371/journal.pntd.0000224.t003
Table 4. Generalised Symptoms Reported and the % Possibly or Probably Related to Vaccine.
Reaction Group A 4-site Group B 8-site Group D 2-site Group E IM P-value
Shivery 7/9 (78%) 5/11 (45%) 4/6 (67%) 3/6 (50%) 0.5
Vomited 2/2 (100%) 0/1 (0%) 0/3 (0%) 0/2 (0%) 0.07
Musc/joint 11/15 (73%) 13/25 (52%) 7/11 (64%) 4/12 (31%) 0.2
Headache 25/32 (78%) 23/39 (59%) 21/32 (66%) 9/22 (41%) 0.05
Diarrhoea 5/6 (83%) 2/4 (50%) 1/3 (33%) 0/1 (0%) 0.3
Rash 4/4 (100%) 4/4 (100%) 2/3 (67%) 1/1 (100%) 0.3
Any generalised symptoms 33/34 (97%) 31/34 (91%) 26/28 (93%) 13/14 (93%) 0.8
Any local or generalised signs or
symptoms
55 (100%) 58 (96.7%) 54 (93.1%) 35 (62.5%) ,0.0001*
*Post hoc test: A vs E, P,0.0001; B vs E, P,0.001; D vs E, P,0.001
doi:10.1371/journal.pntd.0000224.t004
Table 5. RFFIT Serology Results.
Group A 4-site Group B 8-site Group D 2-site Group E IM
Day 7
N5 5 5 8 5 8 5 6
GMT* 0.44 0.67 0.88 0.36
Range (0.02 to 6.89) (0.06 to 6.21) (0.2 to 8.39) (0.02 to 2.79)
95% CI (0.31 to 0.61) (0.53 to 0.86) (0.69 to 1.11) (0.26 to 0.50)
Day 14
N5 4 5 8 5 8 5 4
GMT* 334.66 308.11 363.66 228.45
Range (43.7 to 811.5) (24.3 to 1459.0) (60.9 to 3711.5) (5.5 to 1282.6)
95% CI (278.68 to 401.79) (248.66 to 381.77) (299.16 to 442.08) (161.99 to 322.18)
Day 90
N5 5 5 6 5 8 5 6
GMT* 7.18 9.75 9.14 6.21
Range (0.9 to 29.5) (0.9 to 153.1) (1.2 to 228.9) (0.9 to 81.9)
95% CI (5.63 to 9.15) (7.46 to 12.76) (6.86 to 12.20) (4.86 to 7.95)
1y e a r
N4 4 5 0 5 5 5 3
GMT* 2.52 3.21 4.60 1.33
Range (0.35 to 58.34) (0.36 to 31.71) (0.62 to 295.17) (0.10 to 6.32)
95% CI (1.79 to 3.55) (2.38 to 4.34) (3.31 to 6.42) (1.05 to 1.69)
*IU/ml.
doi:10.1371/journal.pntd.0000224.t005
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individual variation, as demonstrated graphically in a Bland-Altman
plot (Figure 5). Further analysis was not appropriate in such a small
sample. All the FAVN results were ,6 IU/ml, except one of
13.5 IU/ml (the RFFIT result was 2.8 IU/ml). For the RFFIT, all
titres were ,7 IU/ml, except two of 8.39 and 9.36 IU/ml (the
FAVN results were 1.14 and 3.42 IU/ml respectively).
The day 0 sera with RFFIT results .0.3 IU/ml, and day 14 sera
with RFFIT results .3000 IU/ml, were included in a group of 38
otherwise randomly selected sera to be tested by the FAVN method.
Figure 2. Rabies neutralising antibody results by the rabies fluorescent focus inhibition test (RFFIT). Symbols represent: $ Group A 4-
site; m Group B 8-site; x Group D 2-site; % Group E intramuscular (IM). Points are geometric mean titres with 95% confidence intervals.
doi:10.1371/journal.pntd.0000224.g002
Figure 3. Day 14 rabies fluorescent focus inhibition test (RFFIT) results antibody levels $0.5 IU/ml: difference in proportion
between the geometric mean titres (GMTs) of any two regimens. Group A=4-site intradermal (ID); Group B=8-site ID; Group D=2-site ID;
Group E=intramuscular.
doi:10.1371/journal.pntd.0000224.g003
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the FAVN. RFFIT results of 3711.5 and 3021.5 IU/ml were 53.3
and 121.2 IU/ml respectively by the FAVN.
Discussion
Interpretation
This study demonstrates that ID rabies vaccination is at least as
immunogenic as the standard IM regimen and induces greater
persistent immunity. ID regimens are therefore recommended
anywhere in the world where the cost of PEP is critical. All three
ID regimens required the same total amount of vaccine and
proved equally immunogenic, but the 4-site ID regimen has
several key advantages.
Advantages over the 2-site regimen
First, the 4-site needs one less clinic visit (omitting day 3). WHO
now recommends omitting the day 90 dose of ID regimens, and
doubling the day 28 dose [24,25,26]. The 4-site regimen would
then require only 3 visits (days 0, 7 and 28) the same as the current
3 dose IM pre-exposure regimen, but using only about half the
amount of vaccine.
Secondly, the 4-site regimen is safer than the 2-site as it uses a
whole ampoule of vaccine divided between intradermal sites on
the crucial first day. If some vaccine were inadvertently injected
subcutaneously, the wide margin of safety would ensure an
adequate immune response [27]. Thirdly, sharing of ampoules of
vaccine between patients is only necessary on days 7 and 28. The
4-site regimen can therefore be started in a rural clinic with
referral a week later. It is economical anywhere if two or more
people are treated on the same day.
Advantages over the 8-site method
The 4-site regimen can be used economically with current
vaccines formulated in 0.5 and 1.0 ml ampoule sizes. Our results
show that there is no need to divide the initial dose between 8 sites,
because it was equally immunogenic in 4 sites. We injected over
the deltoid and thigh areas, whereas Ambrozaitis et al. [16] used
deltoid and suprascapular sites. The choice might be important in
cultures where there is reluctance to expose the thighs.
Suppression of immune response by concomitant RIG
treatment
The efficacy of the 8-site regimen has been demonstrated in
patients bitten by proved rabid animals, with and without
concomitant RIG [6]. Since the 4-site method has the same
timing of doses and amount of vaccine, and is equally
immunogenic, it can be inferred that RIG treatment would
not be significantly immunosuppressive. All authorities recom-
mend the combination of RIG with vaccine for PEP, especially
Table 6. FAVN Serology Results for Day 7.
Group A 4-site Group B 8-site Group D 2-site Group E IM
N5 4 5 7 5 8 5 5
GMT* 0.673 0.907 1.044 0.573
Range (0.13 to 4.50) (0.10 to 5.92) (0.10 to 5.92) (0.06 to 13.5)
95% CI (0.52 to 0.87) (0.70 to 1.18) (0.82 to 1.32) (0.42 to 0.78)
*IU/ml.
doi:10.1371/journal.pntd.0000224.t006
Figure 4. Rabies fluorescent focus inhibition test (RFFIT) results of the day 7 sera plotted with the results of the same sera tested by
the fluorescent antibody virus neutralisation (FAVN) method. Symbols represent: $ Group A 4-site; m Group B 8-site; x Group D 2-site; %
Group E IM. Points are geometric mean titres with 95% confidence intervals.
doi:10.1371/journal.pntd.0000224.g004
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inevitable in severe cases (bites on the head, neck or hands or
multiple bites) if vaccine is given alone. However RIG is not
generally available or affordable in developing countries where
it is given to ,1% of PEP patients for whom it is recommended
[28]. The 4-site regimen fulfils WHO requirements for
immunogenicity for PEP and so could be introduced without
further studies.
ID doses
WHO recommendations have changed since 1997, when the
difference in dilution was recognised [15], to the latest rule that an
ID dose of either vaccine is 0.1 ml [5,26]. Other studies of 8-site
PVRV have used 0.1 ml per ID site [29], as recommended by
WHO [5], which almost doubles the amount of vaccine used. The
results for the 2-site regimen we report here apply to PVRV, the
equivalent dose for PCECV would be 0.2 ml per site.
Ambrozaitis et al. [16] have tested this 4-site regimen to compare
different doses of vaccine. Using PCECV, which is formulated in
1 mlampoule,theyshowedthat0.1 mlperIDsite,alowerdose,was
as immunogenic as 0.1 ml per ID site of PVRV. This confirms the
safety of our 4-site method, in which 0.25 ml of PCECV would be
injected at each ID site on day 0, and 0.2 ml per site subsequently.
Using the lower dose of 0.1 ml per site would sacrifice the
advantages of using a whole ampoule on the first day, but would
be more economical in large treatment centres [13].
Serological testing
The FAVN and the RFFIT tests are identical in principle but
differ in the way their results are read. A comparison between
these tests, performed within the same laboratory, showed close
correlation [20], but there has been no report of inter-laboratory
comparisons. Our data were too few for substantial analysis. In
this study, at least one unusually high level was seen with one test,
but not confirmed by the other. These results were used in the
analysis but did not affect the overall findings or conclusion.
Similarly high individual results have been reported previously,
but not explained [30,31,32]. Rabies immunisation is expensive
and unusual in the UK. Thorough investigations excluded
previous immunisation in the group analysed and so the high
titres cannot be dismissed as an anamnestic response.
Antibody GMTs on days 7 and 14 were much higher, both by
the RFFIT and FAVN than in some other recent studies [16,30].
Over 30 years, no difference has been reported in serological
responses to tissue culture rabies vaccines between people in
America, Europe and Asia. The higher levels found here remain
unexplained. In a 2-site ID vaccine trial in Thailand, antibody
levels varied 2.2 fold between different hospitals [30].
Conclusion
Economical rabies PEP regimens using 2, 4 or 8 initial ID sites
are as immunogenic as the standard IM regimen, but they use
60% less vaccine. The 4-site regimen has several practical
advantages over both currently used regimens, and is the most
economical since only 3 or 4 clinic visits are needed (on days 0, 7
and 28 with optional day 90). Our finding that ID regimens were
at least as immunogenic as the ‘‘gold standard’’ 5 dose IM regimen
should increase confidence in multiple-site ID techniques. The 4-
site regimen is suitable for use anywhere in the world where there
are financial constraints, and especially where 2 or more patients
are likely to be treated on the same day.
Supporting Information
Checklist S1
Found at: doi:10.1371/journal.pntd.0000224.s001 (0.06 MB
DOC)
Protocol S1
Found at: doi:10.1371/journal.pntd.0000224.s002 (0.08 MB
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Figure 5. Bland-Altman plot of the difference between log RFFIT and log FAVN results, and the mean of the two values. Dotted lines
are the 95% agreement limit. RFFIT=rabies fluorescent focus inhibition test, FAVN=fluorescent antibody virus neutralisation.
doi:10.1371/journal.pntd.0000224.g005
Post-Exposure Intradermal Rabies Vaccine
www.plosntds.org 8 April 2008 | Volume 2 | Issue 4 | e224Acknowledgments
We thank Sanofi Pasteur for their generous donation of the vaccine. We
are grateful to other members of the Oxford Vaccine Group especially to:
S. Segal and T. Chantler for their clinical support; to C. Banner and S.
Lewis for technical assistance, and to T. Goddard for carrying out the
FAVN tests. We thank the staff in the veterinary and medical departments
of Bristol University for their help. The co-operation of the University of
Oxford staff in many Departments and Colleges, and the prolonged
enthusiasm of the volunteers is much appreciated.
Author Contributions
Wrote the paper: MJW. Supervised and co-ordinated the project: RM
DAW. Conceived the project: MJW DAW. Contributed to the design,
acquisition, and analysis of data: HB ARF. Performed and interpreted the
statistical analysis: L-MY JJD. Contributed to the design and conduct of
the study: MJW AR JP LD JJD AJP. Critically reviewed the manuscript: L-
MY LD HB JJD ARF SMB RM AJP DAW. All authors approved the final
article. Reviewed the protocol on behalf of the WHO: F-XM. Analysed
and interpreted the serology: LA SMB.
References
1. Knobel DL, Cleaveland S, Coleman PG, Fevre EM, Meltzer MI, et al. (2005)
Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ
83: 360–8.
2. Meslin F-X (2007) Rabies in Asia: Current scene and WHO’s role in control. In:
Conference Proceedings of RIACON-2007 First Conference of Rabies in Asia
(RIA) Foundation. Bangalore, India. 3–4
th March: 2.
3. Mallewa M, Fooks AR, Banda D, Chikungwa P, Mankhambo L, et al. (2007)
Rabies encephalitis in malaria-endemic area, Malawi, Africa. Emerg Infect Dis
13: 136–9.
4. Dodet B (2006) Preventing the incurable: Asian rabies experts advocate rabies
control. Vaccine 24: 3045–9.
5. World Health Organization Expert Consultation on rabies. WHO Technical
Report Series 931 First Report. WHO, (2006). Available: http://www.wpro.
who.int/NR/rdonlyres/B1ED8443-0993-408C-BF09-D1D06A6E1B45/0/
FINALTEXTWHOTechnicalReportSeries090605.pdf Accessed 25 February
2008.
6. Warrell MJ, Nicholson KG, Warrell DA, Suntharasamai P, Chanthavanich P, et
al. (1985) Economical multiple-site intradermal immunisation with human
diploid- cell-strain vaccine is effective for post-exposure rabies prophylaxis.
Lancet i: 1059–62.
7. Chutivongse S, Wilde H, Supich C, Baer GM, Fishbein DB (1990) Postexposure
prophylaxis for rabies with antiserum and intradermal vaccination. Lancet 335:
896–8.
8. Strady C, Jaussaud R, Beguinot I, Lienard M, Strady A (2000) Predictive factors
for the neutralizing antibody response following pre-exposure rabies immuni-
zation: validation of a new booster dose strategy. Vaccine 18: 2661–7.
9. Jaijaroensup W, Tantawichien T, Khawplod P, Tepsumethanon S, Wilde H
(1999) Postexposure rabies vaccination in patients infected with human
immunodeficiency virus. Clin Infect Dis 28: 913–4.
10. Deshpande A, Briggs DJ, Branzhoff A (2000) Investigation of immune responses
to purified chick embryo cell tissue culture rabies vaccine (PCECV) in HIV
infrected individuals using a simulated post-exposure regimen. In: Proceedings of
XIII International AIDS conference. Durban, South Africa. July 9–14. pp
163–8.
11. Tantawichien T, Jaijaroensup W, Khawplod P, Sitprija V (2001) Failure of
multiple-site intradermal postexposure rabies vaccination in patients with human
immunodeficiency virus with low CD4+ T lymphocyte counts. Clin Infect Dis
33: E122–4.
12. Thisyakorn U, Pancharoen C, Ruxrungtham K, Ubolyam S, Khawplod P, et al.
(2000) Safety and immunogenicity of preexposure rabies vaccination in children
infected with human immunodeficiency virus type 1. Clin Infect Dis 30: 218.
13. Goswami A, Plun-Favreau J, Nicoloyannis N, Sampath G, Siddiqui MN, et al.
(2005) The real cost of rabies post-exposure treatments. Vaccine 23: 2970–6.
14. Warrell MJ (2003) The challenge to provide affordable rabies post-exposure
treatment. Vaccine 21: 706–9.
15. World Health Organization (1997) WHO Recommendations on rabies post-
exposure treatment and the correct technique of intradermal immunization
against rabies. WHO/EMC/ZOO.96.6. WHO, 1997. Available: http://
whqlibdoc.who.int/hq/1996/WHO_EMC_ZOO_96.6.pdf Accessed 25
February 2008.
16. Ambrozaitis A, Laiskonis A, Balciuniene L, Banzhoff A, Malerczyk C (2006)
Rabies post-exposure prophylaxis vaccination with purified chick embryo cell
vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site
intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical
regimen. Vaccine 24: 4116–21.
17. Pappaioanou M, Fishbein DB, Dreesen DW, Schwartz IK, Campbell GH, et al.
(1986) Antibody response to preexposure human diploid-cell rabies vaccine
given concurrently with chloroquine. N Engl J Med 314: 280–4.
18. Bourhy H, Sureau P (1990) Laboratory methods for rabies diagnosis. Paris:
Institut Pasteur. pp 191–3.
19. Feyssaguet M, Dacheux L, Audry L, Compoint A, Morize JL, et al. (2007)
Multicenter comparative study of a new ELISA, PLATELIA RABIES II, for the
detection and titration of anti-rabies glycoprotein antibodies and comparison
with the rapid fluorescent focus inhibition test (RFFIT) on human samples from
vaccinated and non-vaccinated people. Vaccine 25: 2244–51.
20. Cliquet F, Aubert M, Sagne L (1998) Development of a fluorescent antibody
virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising
antibody. J Immunol Methods 212: 79–87.
21. OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 5
th
Edition (2004) Chapter 2.2.5. Rabies. OIE, Available: http://www.oie.int/Eng/
Normes/Mmanual/A_00044.htm Accessed 25 February 2008.
22. Newcombe RG (1998) Interval estimation for the difference between
independent proportions: comparison of eleven methods. Stat Med 17: 873–90.
23. Bland JM, Altman DG (1995) Comparing methods of measurement: why
plotting difference against standard method is misleading. Lancet 346: 1085–7.
24. Khawplod P, Tantawichien T, Wilde H, Limusanno S, Saikasem A, et al. (2002)
Use of rabies vaccines after reconstitution and storage. Clin Infect Dis 34: 404–6.
25. Khawplod P, Wilde H, Sirikwin S, Benjawongkulchai M, Limusanno S, et al.
(2006) Revision of the Thai Red Cross intradermal rabies post-exposure regimen
by eliminating the 90-day booster injection. Vaccine 24: 3084–6.
26. World Health Organization (2007) Rabies vaccines. WHO position paper. Wkly
Epidemiol Rec 82: 425–435. Available: http://www.who.int/wer/2007/
wer8249_50.pdf Accessed 25 February 2008.
27. Suntharasamai P, Warrell MJ, Viravan C, Chanthavanich P, Looareesuwan S,
et al. (1987) Purified chick embryo cell rabies vaccine: economical multisite
intradermal regimen for post-exposure prophylaxis. Epidemiol Infect 99:
755–65.
28. Meslin FX (2005) Rabies as a traveler’s risk, especially in high-endemicity areas.
J Travel Med 12 Suppl 1: S30–40.
29. Khawplod P, Wilde H, Tepsumethanon S, Limusanno S, Tantawichien T, et al.
(2002) Prospective immunogenicity study of multiple intradermal injections of
rabies vaccine in an effort to obtain an early immune response without the use of
immunoglobulin. Clin Infect Dis 35: 1562–5.
30. Briggs DJ, Banzhoff A, Nicolay U, Sirikwin S, Dumavibhat B, et al. (2000)
Antibody response of patients after postexposure rabies vaccination with small
intradermal doses of purified chick embryo cell vaccine or purified Vero cell
rabies vaccine. Bull World Health Organ 78: 693–8.
31. Moore SM, Ricke TA, Davis RD, Briggs DJ (2005) The influence of homologous
vs. heterologous challenge virus strains on the serological test results of rabies
virus neutralizing assays. Biologicals 33: 269–76.
32. Suntharasamai P, Chanthavanich P, Supanaranond W, Warrell MJ (1988) One
year booster vaccination with purified vero cell rabies vaccine. Trans R Soc
Trop Med Hyg 82: 633.
Post-Exposure Intradermal Rabies Vaccine
www.plosntds.org 9 April 2008 | Volume 2 | Issue 4 | e224